Skip to main content
Top
Published in: Journal of Cardiothoracic Surgery 1/2023

Open Access 01-12-2023 | NSCLC | Research

Salvage surgery for advanced non-small cell lung cancer following previous immunotherapy: a retrospective study

Authors: Mitsunori Higuchi, Sho Inomata, Hikaru Yamaguchi, Takuro Saito, Hiroyuki Suzuki

Published in: Journal of Cardiothoracic Surgery | Issue 1/2023

Login to get access

Abstract

Background

The development of systemic chemotherapy including immune checkpoint inhibitors (ICIs) has provided patients with unresectable advanced non-small cell lung cancer (NSCLC) an opportunity to undergo surgical intervention after initial treatment. However, no consensus regarding the indication for salvage surgery in these patients has been reached.

Methods

We conducted a retrospective study of patients who underwent salvage surgery for advanced NSCLC (cStage IIIA–IVB) after treatment with ICIs from January 2018 to December 2022 at Aizu Medical Center and Fukushima Medical University Hospital. We evaluated the patients’ clinical data, calculated disease-free survival (DFS) and overall survival (OS), and assessed the survival benefit using the Kaplan–Meier method.

Results

Thirteen patients underwent salvage surgery after immunotherapy. All patients achieved downstaging after initial chemotherapy. Eleven patients underwent lobectomy, and one patient underwent extirpation of intra-abdominal lymph nodes. The mean surgery time and intraoperative blood loss were 242.2 min and 415.1 g, respectively. The mean drainage period was 4.2 days (range, 2–9 days). Grade ≥ 3 postoperative complications were confirmed in three patients. The 2-year DFS rate was 71.2%, and the 2-year OS rate was 76.2%. A pathological complete response compatible with ypStage 0 was achieved in four (30.8%) patients. Patients with ypStage 0 and I achieved significantly better OS than those with ypStage ≥ II (p = 0.044), and patients without severe complications achieved significantly better DFS and OS than those with severe complications (p = 0.001 and p < 0.001, respectively).

Conclusions

Salvage surgery after chemotherapy including ICIs is a feasible and effective treatment option for patients with advanced NSCLC, especially those who acquire downstaging to pathological stage 0 or I. However, severe perioperative complications might affect patient survival. A prospective study is urgently needed to evaluate the efficacy of salvage surgery.
Literature
2.
go back to reference Osmani L, Askin F, Gabrielson E, Li QK. Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): moving from targeted therapy to immunotherapy. Semin Cancer Biol. 2018;52:103–9.CrossRefPubMed Osmani L, Askin F, Gabrielson E, Li QK. Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): moving from targeted therapy to immunotherapy. Semin Cancer Biol. 2018;52:103–9.CrossRefPubMed
3.
go back to reference Jemal A, Bray F, Center MM, Ferkay J, Ward E, Forman D. Neoadjuvant and adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer. Transl Lung Cancer Res. 2015;4:82–93. Jemal A, Bray F, Center MM, Ferkay J, Ward E, Forman D. Neoadjuvant and adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer. Transl Lung Cancer Res. 2015;4:82–93.
4.
go back to reference Bott MN, Cools-Lartigue J, Tan KS, Dycoco J, Bains MS, Downey RJ, et al. Safety and feasibility of lung resection after immunotherapy for metastatic or unresectable tumors. Ann Thorac Surg. 2018;106:178–83.CrossRefPubMedPubMedCentral Bott MN, Cools-Lartigue J, Tan KS, Dycoco J, Bains MS, Downey RJ, et al. Safety and feasibility of lung resection after immunotherapy for metastatic or unresectable tumors. Ann Thorac Surg. 2018;106:178–83.CrossRefPubMedPubMedCentral
5.
go back to reference Li K, Cao X, Ai B, Xiao H, Huang Q, Zhang Z, et al. Salvage surgery following downstaging of advanced non-small cell lung cancer by targeted therapy. Thorac Cancer. 2021;12:2161–9.CrossRefPubMedPubMedCentral Li K, Cao X, Ai B, Xiao H, Huang Q, Zhang Z, et al. Salvage surgery following downstaging of advanced non-small cell lung cancer by targeted therapy. Thorac Cancer. 2021;12:2161–9.CrossRefPubMedPubMedCentral
6.
go back to reference Adachi K, Kuroda H, Tanahashi M, Takao M, Ohde Y, Yokoi K, et al. Survival benefits of salvage surgery for primary lung cancer based on routine clinical practice. Thorac Cancer. 2021;12:1716–20.CrossRefPubMedPubMedCentral Adachi K, Kuroda H, Tanahashi M, Takao M, Ohde Y, Yokoi K, et al. Survival benefits of salvage surgery for primary lung cancer based on routine clinical practice. Thorac Cancer. 2021;12:1716–20.CrossRefPubMedPubMedCentral
7.
go back to reference Bauman JE, Mulligan MS, Martins RG, Kurland BF, Eaton KD, Wood DE. Salvage lung resection after definitive radiation (>59Gy) for non-small cell lung cancer: surgical and oncologic outcomes. Ann Thorac Surg. 2008;86:1632–8.CrossRefPubMed Bauman JE, Mulligan MS, Martins RG, Kurland BF, Eaton KD, Wood DE. Salvage lung resection after definitive radiation (>59Gy) for non-small cell lung cancer: surgical and oncologic outcomes. Ann Thorac Surg. 2008;86:1632–8.CrossRefPubMed
9.
go back to reference Song W, Di S, Liu J, Fan B, Zhao J, Zhou S, et al. Salvage surgery for advanced non-small cell lung cancer after targeted therapy: a case series. Thorac Cancer. 2020;11:1061–7.CrossRefPubMedPubMedCentral Song W, Di S, Liu J, Fan B, Zhao J, Zhou S, et al. Salvage surgery for advanced non-small cell lung cancer after targeted therapy: a case series. Thorac Cancer. 2020;11:1061–7.CrossRefPubMedPubMedCentral
10.
go back to reference Nakanishi K, Mizuno T, Sakakura N, Kuroda H, Shimizu J, Hida T, et al. Salvage surgery for small cell lung cancer after chemoradiotherapy. Jpn J Clin Oncol. 2019;49:389–92.CrossRefPubMed Nakanishi K, Mizuno T, Sakakura N, Kuroda H, Shimizu J, Hida T, et al. Salvage surgery for small cell lung cancer after chemoradiotherapy. Jpn J Clin Oncol. 2019;49:389–92.CrossRefPubMed
11.
go back to reference Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386:1973–85.CrossRefPubMedPubMedCentral Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386:1973–85.CrossRefPubMedPubMedCentral
12.
go back to reference Wu YL, Tsuboi M, He J, John T, Grohe C, Najem M, et al. ADAURA investigators. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2020;383:1711–23.CrossRefPubMed Wu YL, Tsuboi M, He J, John T, Grohe C, Najem M, et al. ADAURA investigators. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2020;383:1711–23.CrossRefPubMed
13.
go back to reference Felip E, Altorki N, Zhou C, Csöszi T, Vynnychenko I, Goloborodko O, et al. Impower010 Investigators. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomized, multicenter, open-label, phase 3 trial. Lancet. 2021;398:1344–57.CrossRefPubMed Felip E, Altorki N, Zhou C, Csöszi T, Vynnychenko I, Goloborodko O, et al. Impower010 Investigators. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomized, multicenter, open-label, phase 3 trial. Lancet. 2021;398:1344–57.CrossRefPubMed
14.
go back to reference O’Brian M, Paz-Ares L, Marreaud S, Dafni U, Oselin K, Havel L, et al. EORTC-1416-LCG/ETOP 8-15-PEARLS/LEYNOTE-091 Investigators. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomized, triple-blind, phase 3 trial. Lancet. 2022;23:1274–86. O’Brian M, Paz-Ares L, Marreaud S, Dafni U, Oselin K, Havel L, et al. EORTC-1416-LCG/ETOP 8-15-PEARLS/LEYNOTE-091 Investigators. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomized, triple-blind, phase 3 trial. Lancet. 2022;23:1274–86.
15.
go back to reference Tray N, Weber JS, Adams S. Predictive biomarkers for checkpoint immunotherapy: current status and challenges for clinical application. Cancer Immunol Res. 2018;6:1122–8.CrossRefPubMed Tray N, Weber JS, Adams S. Predictive biomarkers for checkpoint immunotherapy: current status and challenges for clinical application. Cancer Immunol Res. 2018;6:1122–8.CrossRefPubMed
16.
go back to reference Jiang T, Bai Y, Zhou F, Li W, Gao G, Su C, et al. Clinical value of neutron-to-lymphocyte ratio in patients with non-small-cell lung cancer treated with PD-1/PD-L1 inhibitors. Lung Cancer. 2019;130:76–83.CrossRefPubMed Jiang T, Bai Y, Zhou F, Li W, Gao G, Su C, et al. Clinical value of neutron-to-lymphocyte ratio in patients with non-small-cell lung cancer treated with PD-1/PD-L1 inhibitors. Lung Cancer. 2019;130:76–83.CrossRefPubMed
17.
go back to reference Higuchi M, Kawamata T, Oshibe I, Soeta N, Saito T, Hojo H, et al. Complete pathological response after immune-checkpoint inhibitor followed by salvage surgery for clinical stage IV pulmonary adenocarcinoma with continuous low neutrophil-to lymphocyte ratio. Case Rep Oncol. 2021;14:1124–33.CrossRefPubMedPubMedCentral Higuchi M, Kawamata T, Oshibe I, Soeta N, Saito T, Hojo H, et al. Complete pathological response after immune-checkpoint inhibitor followed by salvage surgery for clinical stage IV pulmonary adenocarcinoma with continuous low neutrophil-to lymphocyte ratio. Case Rep Oncol. 2021;14:1124–33.CrossRefPubMedPubMedCentral
Metadata
Title
Salvage surgery for advanced non-small cell lung cancer following previous immunotherapy: a retrospective study
Authors
Mitsunori Higuchi
Sho Inomata
Hikaru Yamaguchi
Takuro Saito
Hiroyuki Suzuki
Publication date
01-12-2023
Publisher
BioMed Central
Published in
Journal of Cardiothoracic Surgery / Issue 1/2023
Electronic ISSN: 1749-8090
DOI
https://doi.org/10.1186/s13019-023-02310-5

Other articles of this Issue 1/2023

Journal of Cardiothoracic Surgery 1/2023 Go to the issue